CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema...
Phase 2
Rancho Santa Margarita, California, United States and 12 other locations
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...
Phase 3
Los Angeles, California, United States and 75 other locations
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
Phase 2
Lancaster, California, United States and 2 other locations
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...
Phase 2
Los Angeles, California, United States and 35 other locations
the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.OpSCF or placebo will be adm...
Phase 2
Inglewood, California, United States of America and 21 other locations
The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis a...
Phase 1
Sherman Oaks, California, United States of America and 7 other locations
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Phase 2
Los Angeles, California, United States and 16 other locations
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema ...
Phase 4
Los Angeles, California, United States of America and 74 other locations
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...
Phase 2
Los Angeles, California, United States and 26 other locations
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Phase 2
Los Angeles, California, United States and 22 other locations
Clinical trials
Research sites
Resources
Legal